• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by CorVel Corp.

    12/13/24 4:30:30 PM ET
    $CRVL
    Specialty Insurers
    Finance
    Get the next $CRVL alert in real time by email
    8-K
    CORVEL CORP false 0000874866 0000874866 2024-12-13 2024-12-13

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 13, 2024

     

     

    CORVEL CORPORATION

    (Exact name of registrant as specified in charter)

     

     

     

    Delaware   000-19291   33-0282651
    (State or other jurisdiction
    of incorporation)
     

    (Commission

    file number)

      (IRS Employer
    Identification No.)

     

    5128 Apache Plume Road, Suite 400, Fort Worth, Texas   76109
    (Address of principal executive offices)   (Zip code)

    (817) 390-1416

    (Registrant’s telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.0001 per share   CRVL   The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 8.01.

    Other Events.

    Board Approval of Forward Stock Split and Authorized Share Increase

    On December 13, 2024, the board of directors (the “Board”) of CorVel Corporation (the “Company”) approved (i) a three-for-one forward stock split (the “Stock Split”) of the Company’s common stock, par value $0.0001 (“Common Stock”), and (ii) a proportionate increase in the number of authorized shares of Common Stock from 120,000,000 shares to 360,000,000 shares (the “Authorized Share Increase”). The Board did not approve an increase in the number of authorized shares of the Company’s preferred stock, par value $0.0001 (the “Preferred Stock”), which will remain at 1,000,000 shares.

    The Company expects to file an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Charter Amendment”) with the Secretary of the State of Delaware to implement the Stock Split and Authorized Share Increase on December 24, 2024. Pursuant to Section 242(d)(1) of the Delaware General Corporation Law, no meeting or vote of the Company’s stockholders is required in connection with the filing of the Certificate of Amendment, and the implementation of the Stock Split and Authorized Share Increase.

    Following the filing and effectiveness of the Charter Amendment, every one share of Common Stock outstanding or held as treasury stock on December 23, 2024, the record date for the Stock Split, shall be subdivided and reclassified into three shares of Common Stock. The Stock Split will not result in any change in the par value of the Common Stock or Preferred Stock.

    Subject to final approval by the Nasdaq Global Select Market, trading is currently expected to begin on a post-Stock Split adjusted basis at market open on December 26, 2024.

    As a result of the Stock Split, proportionate adjustments will be made to the number of shares of Common Stock issuable under the Company’s equity incentive plans and the number of shares underlying outstanding equity awards, as well as to the exercise price of outstanding stock options.

    The Board reserves the right to abandon the Stock Split and Authorized Share Increase at any time prior to effectiveness of the Certificate of Amendment.

    Issuance of Press Release

    A copy of the press release announcing Board approval of the Stock Split and Authorized Share Increase is attached hereto as Exhibit 99.1. The information contained in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly set forth by specific reference in such filing.

    Cautionary Note Regarding Forward-Looking Statements

    This Current Report on Form 8-K (‘Current Report”) contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which statements are subject to considerable risks and uncertainties. Forward-looking statements include all statements other than statements of historical fact contained in this Current Report, including statements regarding the implementation and timing of the Stock Split and Authorized Share Increase, and the timing of trading on a post-Stock Split basis. Forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed, assumed, or implied by the forward-looking statements. Some of the risks and uncertainties that may cause actual results to materially differ from those expressed or implied by these forward-looking statements are described in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024, as well as in the Company’s Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Any forward-looking statement made in this Current Report is based only on information currently available to the Company and speaks only as of the date on which it is made. Except as required by applicable law or the listing rules of the Nasdaq Global Select Market, the Company expressly disclaims any intent or obligation to update any forward-looking statements, or to update the reasons actual results could differ materially from those expressed or implied by these forward-looking statements, whether to conform such statements to actual results or changes in expectations, or as a result of the availability of new information.


    Item 9.01.

    Financial Statements and Exhibits

     

      (d)

    Exhibits

     

    Exhibit
    No.
       Description
    99.1    Press Release, dated December 13, 2024
    104    Cover Page Interaction Data File, formatted in Inline XBRL


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        CORVEL CORPORATION
    Dated: December 13, 2024     By:  

    /s/ Richard Schweppe

        Name:   Richard Schweppe
        Its:   Secretary
    Get the next $CRVL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRVL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CRVL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CorVel Announces Revenues and Earnings

      FORT WORTH, Texas, May 22, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ:CRVL) announced the results for the quarter and fiscal year ended March 31, 2025. Revenues for the quarter were $232 million, an increase from $207 million in the March quarter of 2024. Earnings per share for the quarter were $0.51, compared to $0.37 in the same quarter of the prior year.  Revenues for the fiscal year ended March 31, 2025 were $896 million, an increase from $795 million during the fiscal year ended March 31, 2024. Earnings per share for the fiscal year ended March 31, 2025 were $1.83, compared to $1.47 during the fiscal year ended March 31, 2024. The earnings per share numbers for the current an

      5/22/25 6:15:00 AM ET
      $CRVL
      Specialty Insurers
      Finance
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • CorVel Earns 2025 Great Place To Work Certification™

      FORT WORTH, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDQ:CRVL) is proud to be Certified™ by Great Place To Work® for the fifth year in a row. The prestigious award is based entirely on what current employees say about their experience working at CorVel. Great Place To Work® is the global authority on workplace culture, employee experience, and leadership behaviors proven to deliver market-leading revenue, employee retention, and increased innovation. "We are very pleased to be recognized as a Great Place To Work for a 5th consecutive year. CorVel is committed to being an organization where people can learn, grow, and advance, and we are grateful for the team members

      2/25/25 7:05:00 AM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    Leadership Updates

    Live Leadership Updates

    See more
    • CorVel Corporation Appoints Sarah Scott as Executive Vice President of Product

      FORT WORTH, Texas, Feb. 13, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDQ: CRVL), a national provider of risk management solutions, today announced the promotion of Sarah Scott to Executive Vice President of Product. In her expanded role, Sarah will be responsible for defining and driving the overall product vision and strategy, from ideation to launch and ongoing optimization. Sarah's leadership will ensure the company continues to deliver innovative solutions that create value and meet the evolving needs of its partners. Throughout her 25 years with CorVel, Sarah has been instrumental in the company's success. In her previous role as Vice President of Network Solutions, Sarah playe

      2/13/25 7:25:00 AM ET
      $CRVL
      Specialty Insurers
      Finance
    • CorVel Announces Retirement of V. Gordon Clemons

      FORT WORTH, Texas, Nov. 29, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ:CRVL) announces V. Gordon Clemons is electing to retire as a member of the Company's Board of Directors (the "Board") and as Chairman of the Board, effective November 26, 2024, after 37 years of service. Clemons founded CorVel Corporation in 1988 and has served as Chairman of the Board since the Company went public in 1991. Effective upon Clemons' retirement, Michael G. Combs, the Company's President and Chief Executive Officer, was appointed as the new Chairman of the Board. Clemons has been an advisor to Combs since 2017, and he will continue to be available to Combs as an outside consultant. "Building CorVe

      11/29/24 1:30:00 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • CorVel Appoints Jeff Gurtcheff Vice President of Enterprise Comp

      FORT WORTH, Texas , Feb. 02, 2022 (GLOBE NEWSWIRE) -- CorVel, a national provider of risk management solutions, has named Jeff Gurtcheff as Vice President of Enterprise Comp. With more than 30 years of experience, Gurtcheff brings a deep understanding of the industry with strategic leadership and management expertise. As Vice President of Enterprise Comp, Gurtcheff will refine product vision and strategy related to corporate goals and manage resources responsible for regulatory compliance, claims handling, quality, and standards and procedures. His position will also support product line profit growth by developing improved processes, risk management practices, and analytical reporting.

      2/2/22 7:08:00 AM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    Financials

    Live finance-specific insights

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance

    $CRVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer O'Brien Brandon exercised 750 shares at a strike of $29.23 and covered exercise/tax liability with 472 shares, increasing direct ownership by 2% to 15,961 units (SEC Form 4)

      4 - CORVEL CORP (0000874866) (Issuer)

      5/23/25 9:32:36 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 4 filed by Vice President of Accounting Yoss Jennifer

      4 - CORVEL CORP (0000874866) (Issuer)

      5/19/25 7:02:08 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 4 filed by Chief Information Officer Shishin Maxim

      4 - CORVEL CORP (0000874866) (Issuer)

      5/19/25 6:30:11 PM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    SEC Filings

    See more
    • SEC Form 10-K filed by CorVel Corp.

      10-K - CORVEL CORP (0000874866) (Filer)

      5/23/25 4:30:30 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • CorVel Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CORVEL CORP (0000874866) (Filer)

      5/21/25 7:30:09 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form 144 filed by CorVel Corp.

      144 - CORVEL CORP (0000874866) (Subject)

      2/11/25 5:22:53 PM ET
      $CRVL
      Specialty Insurers
      Finance

    $CRVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CorVel Corp. (Amendment)

      SC 13G/A - CORVEL CORP (0000874866) (Subject)

      2/14/24 6:45:55 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form SC 13G/A filed by CorVel Corp. (Amendment)

      SC 13G/A - CORVEL CORP (0000874866) (Subject)

      2/13/24 5:02:29 PM ET
      $CRVL
      Specialty Insurers
      Finance
    • SEC Form SC 13G/A filed by CorVel Corp. (Amendment)

      SC 13G/A - CORVEL CORP (0000874866) (Subject)

      2/13/24 4:05:36 PM ET
      $CRVL
      Specialty Insurers
      Finance